Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

Launched by NOVIAN HEALTH INC. · Mar 6, 2018

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Novilase® Laser Therapy for women with small malignant (cancerous) breast tumors that are 15 mm or less in size. The goal is to see how well this laser therapy can destroy these tumors compared to the standard treatment, which is surgery called lumpectomy. Previous studies have shown that this laser therapy was very effective, removing 98% of tumors of this size in just one procedure. Researchers aim to achieve at least an 80% success rate, meaning they hope to avoid needing further treatment for most participants.

To participate in this trial, women must be at least 18 years old and have a confirmed diagnosis of a single malignant tumor that meets specific size and location criteria. They should not have significant other health issues that could affect their treatment. Participants will receive the laser therapy and may also need to follow up with radiation or other treatments as recommended by their doctor. This study is currently recruiting eligible women, and it's a chance to be part of research that could improve treatment options for breast cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Females, aged 18 years and older
• • Able to give written informed consent herself
• • Definitive pathologic diagnosis by needle core biopsy
• • Unifocal malignant tumor (T1a-c, N0-1, M0) that does not exceed 15 mm in longest dimension and measures at least 5 mm away from the skin and chest wall, or can be moved at least 5 mm away from the skin and chest wall by injection of saline or local anesthetic
• • No more than 10 mm of calcifications confined to the tumor on imaging
• • Tumor is well visualized through ultrasound or x-ray mammography imaging and amenable to image-guidance therapy (i.e., a tumor which is well visualized through imaging can be identified from surrounding breast tissue and does not have margins obscured by other structures or artifacts on the images)
• • Tumor is well visualized on MRI
• • Subject with mammographic appearance of overall dense parenchymal tissue may be included, as long as a clearly evident marker is present at tumor site
• • Tumor with less than 25% intraductal component, as determined by core biopsy
• • No clinically significant co-morbidities (e.g., chronic illnesses existing simultaneously with and usually independent of breast cancer) that affect life expectancy
• • Subject weight limited to ≤300 lbs. or ≤136 kg
• • Subject agrees to comply with standard of care radiation or adjuvant therapy as prescribed by physician
• Exclusion Criteria:
• • Subject younger than 18 years of age
• • Pregnant or breast-feeding
• • Tumor poorly visualized by ultrasound or x-ray mammography imaging
• • Contraindications to administration of gadolinium-based contrast agent, including: prior allergic reaction to a gadolinium-based contrast agent, moderate to end-stage kidney disease, and/or acute or chronic severe renal insufficiency (Glomerular filtration rate (GFR) \<30ml/min/1.73 sq. meters)
• • Contraindications to MRI according to site guidelines (e.g., cardiac pacemaker, metallic implants)
• • History of severe asthma
• • Tumor measuring greater than 15 mm in longest dimension
• • Microcalcifications that extend beyond target tumor such that overall longest dimension of target tumor and calcifications is longer than 15 mm.
• • Advanced stage breast cancer
• • Tumors that are lobular neoplasm, metastatic carcinoma to breast, sarcoma, Phyllodes tumor, or Paget's disease
• • Tumor with only DCIS with microinvasion
• • Extensive intraductal component in lesion (i.e., \>25%) as determined by core biopsy
• • Subject who is known to be BRCA positive
• • Tumor that is ER/PR/HER2 negative (TNBC)
• • Inability to lie in prone or supine position for one hour
• • Subject who is currently participating in another investigational treatment, device or drug study through follow up that would interfere with this trial
• • Subject without a definitive HER2 test according to ASCO/CAP guidelines